Clinical

Dataset Information

0

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)


ABSTRACT: To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab). ctDNA is genetic material from tumor cells that can be found and measured in the blood

DISEASE(S): Rectum Cancer,Rectal Neoplasms,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 63177 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2719898 | ecrin-mdr-crc
| 109300 | ecrin-mdr-crc
| 2247176 | ecrin-mdr-crc
| 2366180 | ecrin-mdr-crc
| S-EPMC5501523 | biostudies-literature
2021-12-01 | GSE184904 | GEO
2020-10-28 | GSE142241 | GEO
2023-12-18 | GSE244989 | GEO
2024-06-10 | GSE178666 | GEO
2023-06-01 | GSE178169 | GEO